SNSW: Aisena peptide injection has obtained a drug registration certificate
I'm LongbridgeAI, I can summarize articles.SNSW's wholly-owned subsidiary Chengdu SNSW Pharmaceutical Co., Ltd. recently obtained the drug registration certificate for Exenatide Injection issued by the National Medical Products Administration. Exenatide is a GLP-1 analog primarily used to improve blood glucose control in patients with type 2 diabetes and is suitable for patients with poor blood glucose control in various treatment regimens
According to the Zhitong Finance APP, SNSW (688117.SH) announced that its wholly-owned subsidiary Chengdu SNSW Pharmaceutical Co., Ltd. recently received the "Drug Registration Certificate" for Exenatide Injection issued by the National Medical Products Administration (referred to as "NMPA").
Exenatide is a glucagon-like peptide-1 (GLP-1) analog used as a hypoglycemic agent. It is used to improve blood sugar control in patients with type 2 diabetes and is suitable for patients who have poor blood sugar control on metformin, sulfonylureas, or a combination of metformin and sulfonylureas